-
1
-
-
0034937128
-
Role of glycosaminoglycans in inflammation
-
Lever R., et al. Role of glycosaminoglycans in inflammation. Inflammopharmacology 2001, 9:165-169.
-
(2001)
Inflammopharmacology
, vol.9
, pp. 165-169
-
-
Lever, R.1
-
2
-
-
33748048179
-
The role of heparan sulphate in inflammation
-
Parish C.R. The role of heparan sulphate in inflammation. Nat. Rev. Immunol. 2006, 6:633-643.
-
(2006)
Nat. Rev. Immunol.
, vol.6
, pp. 633-643
-
-
Parish, C.R.1
-
3
-
-
24944586023
-
Heparan sulfate and inflammation
-
Parish C.R. Heparan sulfate and inflammation. Nat. Immunol. 2005, 6:861-862.
-
(2005)
Nat. Immunol.
, vol.6
, pp. 861-862
-
-
Parish, C.R.1
-
4
-
-
0035997236
-
Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases
-
Díaz-Nido J., et al. Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 2002, 23:1323-1332.
-
(2002)
Peptides
, vol.23
, pp. 1323-1332
-
-
Díaz-Nido, J.1
-
5
-
-
0034904186
-
Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena
-
Iozzo R.V., San Antonio J.D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 2001, 108:349-355.
-
(2001)
J. Clin. Invest.
, vol.108
, pp. 349-355
-
-
Iozzo, R.V.1
San Antonio, J.D.2
-
6
-
-
0030973187
-
Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated?
-
Rosenberg R.D., et al. Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated?. J. Clin. Invest. 1997, 99:2062-2070.
-
(1997)
J. Clin. Invest.
, vol.99
, pp. 2062-2070
-
-
Rosenberg, R.D.1
-
7
-
-
33749558133
-
Therapeutic value of glycosaminoglycans in cancer
-
Yip G.W., et al. Therapeutic value of glycosaminoglycans in cancer. Mol. Cancer Ther. 2006, 5:2139-2148.
-
(2006)
Mol. Cancer Ther.
, vol.5
, pp. 2139-2148
-
-
Yip, G.W.1
-
8
-
-
0031023713
-
Microbial adherence to and invasion through proteoglycans
-
Rostand K.S., Esko J.D. Microbial adherence to and invasion through proteoglycans. Infect. Immun. 1997, 65:1-8.
-
(1997)
Infect. Immun.
, vol.65
, pp. 1-8
-
-
Rostand, K.S.1
Esko, J.D.2
-
9
-
-
0029549804
-
Protein-glycosaminoglycan interactions: infectiological aspects
-
Sawitzky D. Protein-glycosaminoglycan interactions: infectiological aspects. Med. Microbiol. Immunol. (Berl.) 1996, 184:155-161.
-
(1996)
Med. Microbiol. Immunol. (Berl.)
, vol.184
, pp. 155-161
-
-
Sawitzky, D.1
-
10
-
-
0032788960
-
Glycosaminoglycan-binding microbial proteins in tissue adhesion and invasion: key events in microbial pathogenicity
-
Wadstrom T., Ljungh A.S.A. Glycosaminoglycan-binding microbial proteins in tissue adhesion and invasion: key events in microbial pathogenicity. J. Med. Microbiol. 1999, 48:223-233.
-
(1999)
J. Med. Microbiol.
, vol.48
, pp. 223-233
-
-
Wadstrom, T.1
Ljungh, A.S.A.2
-
11
-
-
56649100319
-
The structure of glycosaminoglycans and their interactions with proteins
-
Gandhi N.S., Mancera R.L. The structure of glycosaminoglycans and their interactions with proteins. Chem. Biol. Drug Des. 2008, 72:455-482.
-
(2008)
Chem. Biol. Drug Des.
, vol.72
, pp. 455-482
-
-
Gandhi, N.S.1
Mancera, R.L.2
-
12
-
-
21744431575
-
The sweet and sour of cancer: glycans as novel therapeutic targets
-
Fuster M.M., Esko J.D. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat. Rev. Cancer 2005, 5:526-542.
-
(2005)
Nat. Rev. Cancer
, vol.5
, pp. 526-542
-
-
Fuster, M.M.1
Esko, J.D.2
-
13
-
-
36849092506
-
Glycan antagonists and inhibitors: a fount for drug discovery
-
Brown J.R., et al. Glycan antagonists and inhibitors: a fount for drug discovery. Crit. Rev. Biochem. Mol. Biol. 2007, 42:481-515.
-
(2007)
Crit. Rev. Biochem. Mol. Biol.
, vol.42
, pp. 481-515
-
-
Brown, J.R.1
-
14
-
-
6444222045
-
Glycomics: a pathway to a class of new and improved therapeutics
-
Shriver Z., et al. Glycomics: a pathway to a class of new and improved therapeutics. Nat. Rev. Drug Discov. 2004, 3:863-873.
-
(2004)
Nat. Rev. Drug Discov.
, vol.3
, pp. 863-873
-
-
Shriver, Z.1
-
15
-
-
3042695376
-
Carbohydrate-based therapeutics
-
Osborn H.M.I., et al. Carbohydrate-based therapeutics. J. Pharm. Pharmacol. 2004, 56:691-702.
-
(2004)
J. Pharm. Pharmacol.
, vol.56
, pp. 691-702
-
-
Osborn, H.M.I.1
-
16
-
-
33845521471
-
Glycomic approaches toward drug development: therapeutically exploring the glycosaminoglycanome
-
Gesslbauer B., Kungl A.J. Glycomic approaches toward drug development: therapeutically exploring the glycosaminoglycanome. Curr. Opin. Mol. Ther. 2006, 8:521-528.
-
(2006)
Curr. Opin. Mol. Ther.
, vol.8
, pp. 521-528
-
-
Gesslbauer, B.1
Kungl, A.J.2
-
17
-
-
33745040961
-
Therapeutic applications of glycosaminoglycans
-
Volpi N. Therapeutic applications of glycosaminoglycans. Curr. Med. Chem. 2006, 13:1799-1810.
-
(2006)
Curr. Med. Chem.
, vol.13
, pp. 1799-1810
-
-
Volpi, N.1
-
18
-
-
34447512941
-
Heparan sulfate-protein interactions: a concept for drug design?
-
Lindahl U. Heparan sulfate-protein interactions: a concept for drug design?. Thromb. Haemost. 2007, 98:109-115.
-
(2007)
Thromb. Haemost.
, vol.98
, pp. 109-115
-
-
Lindahl, U.1
-
19
-
-
0642346833
-
The potential of the molecular diversity of heparin and heparan sulfate for drug development
-
Fugedi P. The potential of the molecular diversity of heparin and heparan sulfate for drug development. Mini Rev. Med. Chem. 2003, 3:659-667.
-
(2003)
Mini Rev. Med. Chem.
, vol.3
, pp. 659-667
-
-
Fugedi, P.1
-
22
-
-
33645468255
-
Emerging anticoagulants: mechanism of action and future potential
-
Klement P., Rak J. Emerging anticoagulants: mechanism of action and future potential. Vnitr. Lek. 2006, 52(Suppl. 1):119-122.
-
(2006)
Vnitr. Lek.
, vol.52
, Issue.SUPPL. 1
, pp. 119-122
-
-
Klement, P.1
Rak, J.2
-
23
-
-
0036283477
-
Selective inhibition of coagulation factors: advances in antithrombotic therapy
-
Bauer K.A. Selective inhibition of coagulation factors: advances in antithrombotic therapy. Semin. Thromb. Hemost. 2002, 28(Suppl. 2):15-24.
-
(2002)
Semin. Thromb. Hemost.
, vol.28
, Issue.SUPPL. 2
, pp. 15-24
-
-
Bauer, K.A.1
-
24
-
-
19744372264
-
Synthetic heparin derivatives as new anticoagulant drugs
-
De Kort M., et al. Synthetic heparin derivatives as new anticoagulant drugs. Drug Discov. Today 2005, 10:769-779.
-
(2005)
Drug Discov. Today
, vol.10
, pp. 769-779
-
-
De Kort, M.1
-
25
-
-
40149097733
-
Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles
-
Alban S. Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles. Hamostaseologie 2008, 28:51-61.
-
(2008)
Hamostaseologie
, vol.28
, pp. 51-61
-
-
Alban, S.1
-
26
-
-
0022368634
-
Contribution of monosaccharide residues in heparin binding to antithrombin III
-
Atha D.H., et al. Contribution of monosaccharide residues in heparin binding to antithrombin III. Biochemistry 1985, 24:6723-6729.
-
(1985)
Biochemistry
, vol.24
, pp. 6723-6729
-
-
Atha, D.H.1
-
27
-
-
0041494802
-
Multiple functional domains of the heparin molecule
-
Oosta G.M., et al. Multiple functional domains of the heparin molecule. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:829-833.
-
(1981)
Proc. Natl. Acad. Sci. U. S. A.
, vol.78
, pp. 829-833
-
-
Oosta, G.M.1
-
28
-
-
4544280219
-
A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew
-
Petitou M., v Boeckel C.A.A. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next? Angew. Chem. Int. Ed. Engl. 2004, 43:3118-3133.
-
(2004)
Chem. Int. Ed. Engl.
, vol.43
, pp. 3118-3133
-
-
Petitou, M.1
v Boeckel, C.A.A.2
-
29
-
-
33748233635
-
The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics
-
Van Boeckel C.A.A., Petitou M. The unique antithrombin III binding domain of heparin: a lead to new synthetic antithrombotics. Angew. Chem. Int. Ed. Engl. 1993, 32:1671-1690.
-
(1993)
Angew. Chem. Int. Ed. Engl.
, vol.32
, pp. 1671-1690
-
-
Van Boeckel, C.A.A.1
Petitou, M.2
-
30
-
-
0037507303
-
Antithrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and its conformational activation
-
Jairajpuri M.A., et al. Antithrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and its conformational activation. J. Biol. Chem. 2003, 278:15941-15950.
-
(2003)
J. Biol. Chem.
, vol.278
, pp. 15941-15950
-
-
Jairajpuri, M.A.1
-
31
-
-
70449598272
-
From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile
-
Petitou M., et al. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb. Haemost. 2009, 102:804-810.
-
(2009)
Thromb. Haemost.
, vol.102
, pp. 804-810
-
-
Petitou, M.1
-
32
-
-
0141886345
-
Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties
-
Avci F.Y., et al. Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties. Curr. Pharm. Des. 2003, 9:2323-2335.
-
(2003)
Curr. Pharm. Des.
, vol.9
, pp. 2323-2335
-
-
Avci, F.Y.1
-
33
-
-
3042857728
-
Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy
-
Turpie A.G.G. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy. Expert Opin. Pharmacother. 2004, 5:1373-1384.
-
(2004)
Expert Opin. Pharmacother.
, vol.5
, pp. 1373-1384
-
-
Turpie, A.G.G.1
-
34
-
-
67650422376
-
Discontinued drugs in 2008: cardiovascular drugs
-
Xu-song Z., Bing-ren X. Discontinued drugs in 2008: cardiovascular drugs. Expert Opin. Investig. Drugs 2009, 18:875-885.
-
(2009)
Expert Opin. Investig. Drugs
, vol.18
, pp. 875-885
-
-
Xu-song, Z.1
Bing-ren, X.2
-
35
-
-
2642617786
-
Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide
-
Herbert J.M., et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998, 91:4197-4205.
-
(1998)
Blood
, vol.91
, pp. 4197-4205
-
-
Herbert, J.M.1
-
36
-
-
33947422061
-
High affinity interaction between a synthetic, highly negatively charged pentasaccharide and alpha- or beta-antithrombin is predominantly due to nonionic interactions
-
Hjelm R., Schedin-Weiss S. High affinity interaction between a synthetic, highly negatively charged pentasaccharide and alpha- or beta-antithrombin is predominantly due to nonionic interactions. Biochemistry 2007, 46:3378-3384.
-
(2007)
Biochemistry
, vol.46
, pp. 3378-3384
-
-
Hjelm, R.1
Schedin-Weiss, S.2
-
37
-
-
0032530648
-
Mechanism of heparin activation of antithrombin: evidence for an induced-fit model of allosteric activation involving two interaction subsites
-
Desai U.R., et al. Mechanism of heparin activation of antithrombin: evidence for an induced-fit model of allosteric activation involving two interaction subsites. Biochemistry 1998, 37:13033-13041.
-
(1998)
Biochemistry
, vol.37
, pp. 13033-13041
-
-
Desai, U.R.1
-
38
-
-
0032571333
-
Mechanism of heparin activation of antithrombin: role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin
-
Desai U.R., et al. Mechanism of heparin activation of antithrombin: role of individual residues of the pentasaccharide activating sequence in the recognition of native and activated states of antithrombin. J. Biol. Chem. 1998, 273:7478-7487.
-
(1998)
J. Biol. Chem.
, vol.273
, pp. 7478-7487
-
-
Desai, U.R.1
-
39
-
-
0028545446
-
Feasible synthesis and biological properties of six 'non-glycosamino' glycan analogues of the antithrombin III binding heparin pentasaccharide
-
Westerduin P., et al. Feasible synthesis and biological properties of six 'non-glycosamino' glycan analogues of the antithrombin III binding heparin pentasaccharide. Bioorg. Med. Chem. 1994, 2:1267-1280.
-
(1994)
Bioorg. Med. Chem.
, vol.2
, pp. 1267-1280
-
-
Westerduin, P.1
-
40
-
-
0026441489
-
Biologically active heparin-like fragments with a " non-glycosamino" glycan structure. Part 2: a tetra-o-methylated pentasaccharide with high affinity for antithrombin III
-
Basten J., et al. Biologically active heparin-like fragments with a " non-glycosamino" glycan structure. Part 2: a tetra-o-methylated pentasaccharide with high affinity for antithrombin III. Bioorg. Med. Chem. Lett. 1992, 2:901-904.
-
(1992)
Bioorg. Med. Chem. Lett.
, vol.2
, pp. 901-904
-
-
Basten, J.1
-
41
-
-
0031445112
-
The anticoagulant activation of antithrombin by heparin
-
Jin L., et al. The anticoagulant activation of antithrombin by heparin. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:14683-14688.
-
(1997)
Proc. Natl. Acad. Sci. U. S. A.
, vol.94
, pp. 14683-14688
-
-
Jin, L.1
-
42
-
-
0037459052
-
Structure of β-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity
-
McCoy A.J., et al. Structure of β-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity. J. Mol. Biol. 2003, 326:823-833.
-
(2003)
J. Mol. Biol.
, vol.326
, pp. 823-833
-
-
McCoy, A.J.1
-
43
-
-
44449100797
-
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders
-
Prandoni P., et al. Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. Expert Opin. Investig. Drugs 2008, 17:773-777.
-
(2008)
Expert Opin. Investig. Drugs
, vol.17
, pp. 773-777
-
-
Prandoni, P.1
-
44
-
-
0010851694
-
A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of subcutaneous SANORG 34006 in healthy male and female elderly volunteers
-
(Abstract 1547)
-
Faaij R.A., et al. A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of subcutaneous SANORG 34006 in healthy male and female elderly volunteers. Thromb. Haemost. 1999, 490-491. (Abstract 1547).
-
(1999)
Thromb. Haemost.
, pp. 490-491
-
-
Faaij, R.A.1
-
45
-
-
0010774310
-
A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of SANORG 34006 in healthy young male volunteers
-
(Abstract 2709)
-
Faaij R.A., et al. A phase I single rising dose study to investigate the safety, tolerance and pharmacokinetics of SANORG 34006 in healthy young male volunteers. Thromb. Haemost. 1999, 853-1853. (Abstract 2709).
-
(1999)
Thromb. Haemost.
, pp. 853-1853
-
-
Faaij, R.A.1
-
46
-
-
9944251352
-
Idraparinux sodium
-
Ma Q., Fareed J. Idraparinux sodium. IDrugs 2004, 7:1028-1034.
-
(2004)
IDrugs
, vol.7
, pp. 1028-1034
-
-
Ma, Q.1
Fareed, J.2
-
47
-
-
0012652251
-
A novel long-acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation
-
PERSIST investigators
-
A novel long-acting synthetic factor Xa inhibitor (idraparinux sodium) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. Blood 2002, 100:301. PERSIST investigators.
-
(2002)
Blood
, vol.100
, pp. 301
-
-
-
48
-
-
19944432311
-
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation
-
Buller H.R., et al. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J. Thromb. Haemost. 2004, 2:47-53.
-
(2004)
J. Thromb. Haemost.
, vol.2
, pp. 47-53
-
-
Buller, H.R.1
-
49
-
-
19944432414
-
A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation
-
Minar E., Investigators T.P. A novel long-acting synthetic factor Xa inhibitor (SanOrg34006) to replace warfarin for secondary prevention in deep vein thrombosis. A phase II evaluation. J. Thromb. Haemost. 2004, 2:540.
-
(2004)
J. Thromb. Haemost.
, vol.2
, pp. 540
-
-
Minar, E.1
Investigators, T.P.2
-
50
-
-
34548712332
-
Extended prophylaxis of venous thromboembolism with idraparinux
-
Buller H.R., et al. Extended prophylaxis of venous thromboembolism with idraparinux. N. Engl. J. Med. 2007, 357:1105-1112.
-
(2007)
N. Engl. J. Med.
, vol.357
, pp. 1105-1112
-
-
Buller, H.R.1
-
51
-
-
34548768174
-
Idraparinux versus standard therapy for venous thromboembolic disease
-
Buller H.R., et al. Idraparinux versus standard therapy for venous thromboembolic disease. N. Engl. J. Med. 2007, 357:1094-1104.
-
(2007)
N. Engl. J. Med.
, vol.357
, pp. 1094-1104
-
-
Buller, H.R.1
-
52
-
-
42549097091
-
Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials
-
Harenberg J., et al. Anticoagulant effects of Idraparinux after termination of therapy for prevention of recurrent venous thromboembolism: observations from the van Gogh trials. Eur. J. Clin. Pharmacol. 2008, 64:555-563.
-
(2008)
Eur. J. Clin. Pharmacol.
, vol.64
, pp. 555-563
-
-
Harenberg, J.1
-
53
-
-
42149173719
-
Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials
-
Harenberg J., et al. Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. J. Thromb. Haemost. 2008, 6:890-892.
-
(2008)
J. Thromb. Haemost.
, vol.6
, pp. 890-892
-
-
Harenberg, J.1
-
54
-
-
78649630436
-
The anticoagulant Idraparinux: is the extensive half life of 60 days the cause of bleeding complications
-
Harenberg J., et al. The anticoagulant Idraparinux: is the extensive half life of 60 days the cause of bleeding complications. Br. J. Clin. Pharmacol. 2009, 68(Suppl. 1):21-121.
-
(2009)
Br. J. Clin. Pharmacol.
, vol.68
, Issue.SUPPL. 1
, pp. 21-121
-
-
Harenberg, J.1
-
55
-
-
1542359508
-
Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers
-
Bijsterveld N.R., et al. Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers. Br. J. Haematol. 2004, 124:653-658.
-
(2004)
Br. J. Haematol.
, vol.124
, pp. 653-658
-
-
Bijsterveld, N.R.1
-
56
-
-
63049084008
-
The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials
-
Veyrat-Follet C., et al. The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. J. Thromb. Haemost. 2009, 7:559-565.
-
(2009)
J. Thromb. Haemost.
, vol.7
, pp. 559-565
-
-
Veyrat-Follet, C.1
-
57
-
-
40749160810
-
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial
-
The AMADEUS Investigators
-
Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008, 371:315-321. The AMADEUS Investigators.
-
(2008)
Lancet
, vol.371
, pp. 315-321
-
-
-
58
-
-
70449598269
-
Development of idraparinux and idrabiotaparinux for anticoagulant therapy
-
Harenberg J. Development of idraparinux and idrabiotaparinux for anticoagulant therapy. Thromb. Haemost. 2009, 102:811-815.
-
(2009)
Thromb. Haemost.
, vol.102
, pp. 811-815
-
-
Harenberg, J.1
-
59
-
-
52449134037
-
Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy
-
Savi P., et al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J. Thromb. Haemost. 2008, 6:1697-1706.
-
(2008)
J. Thromb. Haemost.
, vol.6
, pp. 1697-1706
-
-
Savi, P.1
-
60
-
-
70350254762
-
New anticoagulants for atrial fibrillation
-
Sobieraj-Teague M., et al. New anticoagulants for atrial fibrillation. Semin. Thromb. Hemost. 2009, 35:515-524.
-
(2009)
Semin. Thromb. Hemost.
, vol.35
, pp. 515-524
-
-
Sobieraj-Teague, M.1
-
61
-
-
67649496320
-
Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026
-
Viskov C., et al. Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J. Thromb. Haemost. 2009, 7:1143-1151.
-
(2009)
J. Thromb. Haemost.
, vol.7
, pp. 1143-1151
-
-
Viskov, C.1
-
62
-
-
70349638447
-
AVE5026: a new hemisynthetic ultra low molecular weight heparin (ULMWH) with enriched anti-Xa activity and enhanced antithrombotic activity for management of cancer associated thrombosis
-
(Meeting Abstracts)
-
Hoppensteadt D., et al. AVE5026: a new hemisynthetic ultra low molecular weight heparin (ULMWH) with enriched anti-Xa activity and enhanced antithrombotic activity for management of cancer associated thrombosis. J. Clin. Oncol. 2008, 26(15 Suppl.):14653. (Meeting Abstracts).
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.15 SUPPL.
, pp. 14653
-
-
Hoppensteadt, D.1
-
63
-
-
63049119668
-
AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery - TREK: a dose-ranging study
-
Lassen M.R., et al. AVE5026, a new hemisynthetic ultra-low-molecular-weight heparin for the prevention of venous thromboembolism in patients after total knee replacement surgery - TREK: a dose-ranging study. J. Thromb. Haemost. 2009, 7:566-572.
-
(2009)
J. Thromb. Haemost.
, vol.7
, pp. 566-572
-
-
Lassen, M.R.1
-
64
-
-
70350058915
-
Design and rationale of the evaluation of M118 in percutaneous coronary intervention (EMINENCE) trial
-
Melloni C., et al. Design and rationale of the evaluation of M118 in percutaneous coronary intervention (EMINENCE) trial. Am. Heart J. 2009, 158:726-733.
-
(2009)
Am. Heart J.
, vol.158
, pp. 726-733
-
-
Melloni, C.1
-
65
-
-
70449592260
-
M118-A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes
-
Kishimoto T.K., et al. M118-A rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes. Thromb. Haemost. 2009, 102:900-906.
-
(2009)
Thromb. Haemost.
, vol.102
, pp. 900-906
-
-
Kishimoto, T.K.1
-
66
-
-
77956246541
-
Pharmacokinetics of M118, unfractionated heparin and enoxaparin sodium in normal and 5/6 nephrectomized uremic rats
-
Draganov D., et al. Pharmacokinetics of M118, unfractionated heparin and enoxaparin sodium in normal and 5/6 nephrectomized uremic rats. Toxicol. Lett. 2009, 189(Suppl. 1):S113-S1113.
-
(2009)
Toxicol. Lett.
, vol.189
, Issue.SUPPL. 1
-
-
Draganov, D.1
-
67
-
-
67849114034
-
A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation
-
Volovyk Z., et al. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation. J. Thromb. Thrombolysis 2009, 28:132-139.
-
(2009)
J. Thromb. Thrombolysis
, vol.28
, pp. 132-139
-
-
Volovyk, Z.1
-
68
-
-
78649631067
-
A novel, rationally engineered heparin (M118) prevents thrombosis more effectively than unfractionated heparin in a canine model of deep arterial injury
-
Fier I., et al. A novel, rationally engineered heparin (M118) prevents thrombosis more effectively than unfractionated heparin in a canine model of deep arterial injury. J. Am. Coll. Cardiol. 2007, 49:379A-380A.
-
(2007)
J. Am. Coll. Cardiol.
, vol.49
-
-
Fier, I.1
-
69
-
-
70350536997
-
M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice
-
Chakrabarti S., et al. M118, a novel low-molecular weight heparin with decreased polydispersity leads to enhanced anticoagulant activity and thrombotic occlusion in ApoE knockout mice. J. Thromb. Thrombolysis 2009, 28:394-400.
-
(2009)
J. Thromb. Thrombolysis
, vol.28
, pp. 394-400
-
-
Chakrabarti, S.1
-
70
-
-
77956253909
-
Lack of pharmacokinetic and pharmacodynamic interactions between M118, a novel low-molecular-weight-heparin and Eptifibatide in healthy subjects
-
Fier I.D., et al. Lack of pharmacokinetic and pharmacodynamic interactions between M118, a novel low-molecular-weight-heparin and Eptifibatide in healthy subjects. J. Clin. Pharmacol. 2009, 49:73.
-
(2009)
J. Clin. Pharmacol.
, vol.49
, pp. 73
-
-
Fier, I.D.1
-
74
-
-
70449701596
-
Therapeutic use of heparin beyond anticoagulation
-
Ludwig R.J. Therapeutic use of heparin beyond anticoagulation. Curr. Drug Discov. Technol. 2009, 6:281-289.
-
(2009)
Curr. Drug Discov. Technol.
, vol.6
, pp. 281-289
-
-
Ludwig, R.J.1
-
75
-
-
46749113163
-
The anti-inflammatory effects of heparin and related compounds
-
Young E. The anti-inflammatory effects of heparin and related compounds. Thromb. Res. 2008, 122:743-752.
-
(2008)
Thromb. Res.
, vol.122
, pp. 743-752
-
-
Young, E.1
-
76
-
-
77955482977
-
Antimetastatic activities of heparins and modified heparins. Experimental evidence
-
Borsig L. Antimetastatic activities of heparins and modified heparins. Experimental evidence. Thromb. Res. 2010, 125(Suppl. 2):S66-S71.
-
(2010)
Thromb. Res.
, vol.125
, Issue.SUPPL. 2
-
-
Borsig, L.1
-
77
-
-
34247637147
-
Heparanase: a target for drug discovery in cancer and inflammation
-
McKenzie E.A. Heparanase: a target for drug discovery in cancer and inflammation. Br. J. Pharmacol. 2007, 151:1-14.
-
(2007)
Br. J. Pharmacol.
, vol.151
, pp. 1-14
-
-
McKenzie, E.A.1
-
78
-
-
0034904048
-
Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis
-
Vlodavsky I., Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest. 2001, 108:341-347.
-
(2001)
J. Clin. Invest.
, vol.108
, pp. 341-347
-
-
Vlodavsky, I.1
Friedmann, Y.2
-
79
-
-
33746552708
-
Development of heparanase inhibitors for anti-cancer therapy
-
Miao H.-Q., et al. Development of heparanase inhibitors for anti-cancer therapy. Curr. Med. Chem. 2006, 13:2101-2111.
-
(2006)
Curr. Med. Chem.
, vol.13
, pp. 2101-2111
-
-
Miao, H.-Q.1
-
80
-
-
54949134525
-
PI-88: a novel inhibitor of angiogenesis
-
Kudchadkar R., et al. PI-88: a novel inhibitor of angiogenesis. Expert Opin. Investig. Drugs 2008, 17:1769-1776.
-
(2008)
Expert Opin. Investig. Drugs
, vol.17
, pp. 1769-1776
-
-
Kudchadkar, R.1
-
81
-
-
0037295612
-
The development of the novel angiogenesis inhibitor PI-88 as an anticancer drug
-
Ferro V., Don R. The development of the novel angiogenesis inhibitor PI-88 as an anticancer drug. Australas. Biotechnol. 2003, 13:38-39.
-
(2003)
Australas. Biotechnol.
, vol.13
, pp. 38-39
-
-
Ferro, V.1
Don, R.2
-
82
-
-
0035880995
-
Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides
-
Wall D., et al. Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides. Thromb. Res. 2001, 103:325-335.
-
(2001)
Thromb. Res.
, vol.103
, pp. 325-335
-
-
Wall, D.1
-
83
-
-
33749347624
-
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors
-
Basche M., et al. A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin. Cancer Res. 2006, 12:5471-5480.
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 5471-5480
-
-
Basche, M.1
-
84
-
-
0035985303
-
Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia
-
Rosenthal M.A., et al. Treatment with the novel anti-angiogenic agent PI-88 is associated with immune-mediated thrombocytopenia. Ann. Oncol. 2002, 13:770-776.
-
(2002)
Ann. Oncol.
, vol.13
, pp. 770-776
-
-
Rosenthal, M.A.1
-
85
-
-
53149138189
-
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies
-
Chow L.Q., et al. A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer Chemother. Pharmacol. 2008, 63:65-74.
-
(2008)
Cancer Chemother. Pharmacol.
, vol.63
, pp. 65-74
-
-
Chow, L.Q.1
-
86
-
-
78649630192
-
Final results of a phase I study of daily PI-88 as a single agent and in combination with dacarbazine (D) in patients with metastatic melanoma
-
(Meeting Abstracts)
-
Millward M., et al. Final results of a phase I study of daily PI-88 as a single agent and in combination with dacarbazine (D) in patients with metastatic melanoma. J. Clin. Oncol. 2007, 25(Suppl. 18):8532. (Meeting Abstracts).
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.SUPPL. 18
, pp. 8532
-
-
Millward, M.1
-
87
-
-
77953974391
-
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
-
Khasraw M., et al. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann. Oncol. 2009, 21:1302-1307.
-
(2009)
Ann. Oncol.
, vol.21
, pp. 1302-1307
-
-
Khasraw, M.1
-
88
-
-
38149089538
-
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma
-
Lewis K.D., et al. A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Invest. New Drugs 2008, 26:89-94.
-
(2008)
Invest. New Drugs
, vol.26
, pp. 89-94
-
-
Lewis, K.D.1
-
89
-
-
29744433264
-
Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88)
-
Karoli T., et al. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88). J. Med. Chem. 2005, 48:8229-8236.
-
(2005)
J. Med. Chem.
, vol.48
, pp. 8229-8236
-
-
Karoli, T.1
-
90
-
-
34547092688
-
PI-88 and novel heparan sulfate mimetics inhibit angiogenesis
-
Ferro V., et al. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin. Thromb. Hemost. 2007, 33:557-568.
-
(2007)
Semin. Thromb. Hemost.
, vol.33
, pp. 557-568
-
-
Ferro, V.1
-
91
-
-
77952239575
-
The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy
-
Dredge K., et al. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest. New Drugs 2009, 28:276-283.
-
(2009)
Invest. New Drugs
, vol.28
, pp. 276-283
-
-
Dredge, K.1
-
94
-
-
0038376613
-
Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders
-
van Horssen J., et al. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol. 2003, 2:482-492.
-
(2003)
Lancet Neurol.
, vol.2
, pp. 482-492
-
-
van Horssen, J.1
-
95
-
-
0033572813
-
Interactions of Alzheimer amyloid-β peptides with glycosaminoglycans
-
McLaurin J.A., et al. Interactions of Alzheimer amyloid-β peptides with glycosaminoglycans. Eur. J. Biochem. 1999, 266:1101-1110.
-
(1999)
Eur. J. Biochem.
, vol.266
, pp. 1101-1110
-
-
McLaurin, J.A.1
-
96
-
-
0028278477
-
Binding of heparan sulfate glycosaminoglycan to [beta]-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds
-
Leveugle B., et al. Binding of heparan sulfate glycosaminoglycan to [beta]-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds. Neuroreport 1994, 5:1389-1392.
-
(1994)
Neuroreport
, vol.5
, pp. 1389-1392
-
-
Leveugle, B.1
-
97
-
-
0028913416
-
Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease
-
Kisilevsky R., et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer's disease. Nat. Med. 1995, 1:143-148.
-
(1995)
Nat. Med.
, vol.1
, pp. 143-148
-
-
Kisilevsky, R.1
-
98
-
-
78649633926
-
Functional GAG mimetics as an approach for the treatment of amyloid diseases
-
Tremblay P., et al. Functional GAG mimetics as an approach for the treatment of amyloid diseases. Alzheimers Dement. 2005, 1(Suppl. 1):S2-S12.
-
(2005)
Alzheimers Dement.
, vol.1
, Issue.SUPPL. 1
-
-
Tremblay, P.1
-
99
-
-
34548689646
-
Alzhemed: a potential treatment for Alzheimers disease
-
Aisen P.S., et al. Alzhemed: a potential treatment for Alzheimers disease. Curr. Alzheimer Res. 2007, 4:473-478.
-
(2007)
Curr. Alzheimer Res.
, vol.4
, pp. 473-478
-
-
Aisen, P.S.1
-
102
-
-
33847133125
-
Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis
-
Gervais F., et al. Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging 2007, 28:537-547.
-
(2007)
Neurobiol. Aging
, vol.28
, pp. 537-547
-
-
Gervais, F.1
-
103
-
-
35748977086
-
Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau
-
Santa-Maria I., et al. Tramiprosate, a drug of potential interest for the treatment of Alzheimer's disease, promotes an abnormal aggregation of tau. Mol. Neurodegener. 2007, 2:17.
-
(2007)
Mol. Neurodegener.
, vol.2
, pp. 17
-
-
Santa-Maria, I.1
-
104
-
-
33845388059
-
A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease
-
Aisen P.S., et al. A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006, 67:1757-1763.
-
(2006)
Neurology
, vol.67
, pp. 1757-1763
-
-
Aisen, P.S.1
-
105
-
-
61849185913
-
Recent developments in Alzheimer's disease therapeutics
-
Rafii M.S., Aisen P. Recent developments in Alzheimer's disease therapeutics. BMC Med. 2009, 7:7.
-
(2009)
BMC Med.
, vol.7
, pp. 7
-
-
Rafii, M.S.1
Aisen, P.2
-
106
-
-
65249138789
-
Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the Alzhemed™ (Tramiprosate) experience
-
Saumier D., et al. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer's disease: the Alzhemed™ (Tramiprosate) experience. J. Nutr. Health Aging 2009, 13:370-372.
-
(2009)
J. Nutr. Health Aging
, vol.13
, pp. 370-372
-
-
Saumier, D.1
-
107
-
-
75649105019
-
Current treatment and recent clinical research in Alzheimer's disease
-
Neugroschl J., Sano M. Current treatment and recent clinical research in Alzheimer's disease. Mt. Sinai J. Med. 2010, 77:3-16.
-
(2010)
Mt. Sinai J. Med.
, vol.77
, pp. 3-16
-
-
Neugroschl, J.1
Sano, M.2
-
108
-
-
33750100708
-
Eprodisate sodium
-
Revill P., et al. Eprodisate sodium. Drugs Future 2006, 31:576-578.
-
(2006)
Drugs Future
, vol.31
, pp. 576-578
-
-
Revill, P.1
-
109
-
-
0033548474
-
The heparin/heparan sulfate-binding site on apo-serum Amyloid A
-
Ancsin J.B., Kisilevsky R. The heparin/heparan sulfate-binding site on apo-serum Amyloid A. J. Biol. Chem. 1999, 274:7172-7181.
-
(1999)
J. Biol. Chem.
, vol.274
, pp. 7172-7181
-
-
Ancsin, J.B.1
Kisilevsky, R.2
-
110
-
-
34250019930
-
Proteoglycans and amyloidogenic proteins in peripheral amyloidosis
-
Gervais F., et al. Proteoglycans and amyloidogenic proteins in peripheral amyloidosis. Curr. Med. Chem. Immunol. Endocr. Metab. Agents 2003, 3:361-370.
-
(2003)
Curr. Med. Chem. Immunol. Endocr. Metab. Agents
, vol.3
, pp. 361-370
-
-
Gervais, F.1
-
111
-
-
0034110874
-
The relation of proteoglycans, serum amyloid P and Apo E to amyloidosis current status, 2000
-
Kisilevsky R. The relation of proteoglycans, serum amyloid P and Apo E to amyloidosis current status, 2000. Amyloid 2000, 7:23-25.
-
(2000)
Amyloid
, vol.7
, pp. 23-25
-
-
Kisilevsky, R.1
-
112
-
-
78649632515
-
-
Clinicaltrials.gov. (2002) A phase II/III study of the safety and efficacy of NC-503 in patients suffering from secondary (AA) amyloidosis.
-
Clinicaltrials.gov. (2002) A phase II/III study of the safety and efficacy of NC-503 in patients suffering from secondary (AA) amyloidosis (). ctgov:NCT00035334.
-
-
-
-
113
-
-
34249992082
-
Eprodisate for the treatment of renal disease in AA amyloidosis
-
Dember L.M., et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N. Engl. J. Med. 2007, 356:2349-2360.
-
(2007)
N. Engl. J. Med.
, vol.356
, pp. 2349-2360
-
-
Dember, L.M.1
-
114
-
-
50949108535
-
Eprodisate in amyloid A amyloidosis: a novel therapeutic approach?
-
Manenti L., et al. Eprodisate in amyloid A amyloidosis: a novel therapeutic approach?. Expert Opin. Pharmacother. 2008, 9:2175-2180.
-
(2008)
Expert Opin. Pharmacother.
, vol.9
, pp. 2175-2180
-
-
Manenti, L.1
-
116
-
-
79956267087
-
Small molecule inhibitors of glycosaminoglycan biosynthesis as substrate optimization therapy for the mucopolysaccharidoses
-
Brown J., et al. Small molecule inhibitors of glycosaminoglycan biosynthesis as substrate optimization therapy for the mucopolysaccharidoses. Proceedings of the Lysosomal Disease Network WORLD Symposium, vol. 99 2010, S12-S112.
-
(2010)
Proceedings of the Lysosomal Disease Network WORLD Symposium, vol. 99
-
-
Brown, J.1
-
117
-
-
77956485588
-
Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer
-
Casu B., et al. Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol. 2010, 29:442-452.
-
(2010)
Matrix Biol.
, vol.29
, pp. 442-452
-
-
Casu, B.1
-
118
-
-
34447287858
-
Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate
-
Vlodavsky I., et al. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr. Pharm. Des. 2007, 13:2057-2073.
-
(2007)
Curr. Pharm. Des.
, vol.13
, pp. 2057-2073
-
-
Vlodavsky, I.1
-
119
-
-
33845357884
-
Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin
-
Mousa S.A., et al. Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb. Haemost. 2006, 96:816-821.
-
(2006)
Thromb. Haemost.
, vol.96
, pp. 816-821
-
-
Mousa, S.A.1
-
120
-
-
70449122133
-
Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells
-
Lee D.Y., et al. Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells. Pharm. Res. 2009, 26:2667-2676.
-
(2009)
Pharm. Res.
, vol.26
, pp. 2667-2676
-
-
Lee, D.Y.1
-
122
-
-
85056565879
-
Antitumor activity of EP80061, a small-glyco drug in preclinical studies
-
Serina G., et al. Antitumor activity of EP80061, a small-glyco drug in preclinical studies. Proceedings of the AACR meeting 2010.
-
(2010)
Proceedings of the AACR meeting
-
-
Serina, G.1
-
127
-
-
33646232965
-
Regenerating agents (RGTAs): a new therapeutic approach
-
Barritault D., Caruelle J.P. Regenerating agents (RGTAs): a new therapeutic approach. Ann. Pharm. Fr. 2006, 64:135-144.
-
(2006)
Ann. Pharm. Fr.
, vol.64
, pp. 135-144
-
-
Barritault, D.1
Caruelle, J.P.2
-
128
-
-
0026592363
-
Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF
-
Tardieu M., et al. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF. J. Cell. Physiol. 1992, 150:194-203.
-
(1992)
J. Cell. Physiol.
, vol.150
, pp. 194-203
-
-
Tardieu, M.1
-
129
-
-
0030200049
-
Heparin-like polymers derived from dextran enhance colonic anastomosis resistance to leakage
-
Meddahi A., et al. Heparin-like polymers derived from dextran enhance colonic anastomosis resistance to leakage. J. Biomed. Mater. Res. 1996, 31:293-297.
-
(1996)
J. Biomed. Mater. Res.
, vol.31
, pp. 293-297
-
-
Meddahi, A.1
-
130
-
-
25444472167
-
A synthetic glycosaminoglycan mimetic minds vascular endothelial growth factor and modulates angiogenesis
-
Rouet V., et al. A synthetic glycosaminoglycan mimetic minds vascular endothelial growth factor and modulates angiogenesis. J. Biol. Chem. 2005, 280:32792-32800.
-
(2005)
J. Biol. Chem.
, vol.280
, pp. 32792-32800
-
-
Rouet, V.1
-
131
-
-
0030028218
-
FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives
-
Meddahi A., et al. FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives. Int. J. Biol. Macromol. 1996, 18:141-145.
-
(1996)
Int. J. Biol. Macromol.
, vol.18
, pp. 141-145
-
-
Meddahi, A.1
-
132
-
-
0029586998
-
Inhibition by dextran derivatives of FGF-2 plasmin-mediated degradation
-
Meddahi A., et al. Inhibition by dextran derivatives of FGF-2 plasmin-mediated degradation. Biochimie 1995, 77:703-706.
-
(1995)
Biochimie
, vol.77
, pp. 703-706
-
-
Meddahi, A.1
-
133
-
-
0034703008
-
Human plasmin enzymatic activity is inhibited by chemically modified dextrans
-
Ledoux D., et al. Human plasmin enzymatic activity is inhibited by chemically modified dextrans. J. Biol. Chem. 2000, 275:29383-29390.
-
(2000)
J. Biol. Chem.
, vol.275
, pp. 29383-29390
-
-
Ledoux, D.1
-
134
-
-
33748039731
-
Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro
-
Rouet V., et al. Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro. J. Biomed. Mater. Res. A 2006, 78:792-797.
-
(2006)
J. Biomed. Mater. Res. A
, vol.78
, pp. 792-797
-
-
Rouet, V.1
-
135
-
-
70350666256
-
Matrix therapy in regenerative medicine, a new approach to chronic wound healing
-
Barbier-Chassefière V., et al. Matrix therapy in regenerative medicine, a new approach to chronic wound healing. J. Biomed. Mater. Res. A 2009, 90:641-647.
-
(2009)
J. Biomed. Mater. Res. A
, vol.90
, pp. 641-647
-
-
Barbier-Chassefière, V.1
-
136
-
-
0028076068
-
New approaches to tissue regeneration and repair
-
Meddahi A., et al. New approaches to tissue regeneration and repair. Pathol. Res. Pract. 1994, 190:923-928.
-
(1994)
Pathol. Res. Pract.
, vol.190
, pp. 923-928
-
-
Meddahi, A.1
-
137
-
-
0029881016
-
Modulation of cranial bone healing with a heparin-like dextran derivative
-
Albo D., et al. Modulation of cranial bone healing with a heparin-like dextran derivative. J. Craniofac. Surg. 1996, 7:19-22.
-
(1996)
J. Craniofac. Surg.
, vol.7
, pp. 19-22
-
-
Albo, D.1
-
138
-
-
0029585215
-
Heparan-like molecules induce the repair of skull defects
-
Blanquaert F., et al. Heparan-like molecules induce the repair of skull defects. Bone 1995, 17:499-506.
-
(1995)
Bone
, vol.17
, pp. 499-506
-
-
Blanquaert, F.1
-
139
-
-
0033738410
-
New agents for the treatment of infarcted myocardium
-
Yamauchi H., et al. New agents for the treatment of infarcted myocardium. FASEB J. 2000, 14:2133-2134.
-
(2000)
FASEB J.
, vol.14
, pp. 2133-2134
-
-
Yamauchi, H.1
-
140
-
-
0037024112
-
Heparin-like polymer improved healing of gastric and colic ulceration
-
Meddahi A., et al. Heparin-like polymer improved healing of gastric and colic ulceration. J. Biomed. Mater. Res. 2002, 60:497-501.
-
(2002)
J. Biomed. Mater. Res.
, vol.60
, pp. 497-501
-
-
Meddahi, A.1
-
141
-
-
0141535210
-
A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers
-
Escartin Q., et al. A new approach to treat tissue destruction in periodontitis with chemically modified dextran polymers. FASEB J. 2003, 17:644-651.
-
(2003)
FASEB J.
, vol.17
, pp. 644-651
-
-
Escartin, Q.1
-
142
-
-
0036323139
-
Glycosaminoglycan mimetics (RGTA) modulate adult skeletal muscle satellite cell proliferation in vitro
-
Papy-Garcia D., et al. Glycosaminoglycan mimetics (RGTA) modulate adult skeletal muscle satellite cell proliferation in vitro. J. Biomed. Mater. Res. 2002, 62:46-55.
-
(2002)
J. Biomed. Mater. Res.
, vol.62
, pp. 46-55
-
-
Papy-Garcia, D.1
-
143
-
-
0344845037
-
Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis
-
Schonberger O., et al. Novel heparan mimetics potently inhibit the scrapie prion protein and its endocytosis. Biochem. Biophys. Res. Commun. 2003, 312:473-479.
-
(2003)
Biochem. Biophys. Res. Commun.
, vol.312
, pp. 473-479
-
-
Schonberger, O.1
-
144
-
-
0042854755
-
A novel generation of heparan sulfate mimetics for the treatment of prion diseases
-
Adjou K.T., et al. A novel generation of heparan sulfate mimetics for the treatment of prion diseases. J. Gen. Virol. 2003, 84:2595-2603.
-
(2003)
J. Gen. Virol.
, vol.84
, pp. 2595-2603
-
-
Adjou, K.T.1
-
145
-
-
20944439207
-
A synthetic glycosaminoglycan mimetic (RGTA) modifies natural glycosaminoglycan species during myogenesis
-
Barbosa I., et al. A synthetic glycosaminoglycan mimetic (RGTA) modifies natural glycosaminoglycan species during myogenesis. J. Cell Sci. 2005, 118:253-264.
-
(2005)
J. Cell Sci.
, vol.118
, pp. 253-264
-
-
Barbosa, I.1
-
146
-
-
0028889539
-
Effect of a substituted dextran on reinnervation during regeneration of adult rat skeletal muscle
-
Aamiri A., et al. Effect of a substituted dextran on reinnervation during regeneration of adult rat skeletal muscle. C. R. Acad. Sci. III. Sci. Vie 1995, 318:1037-1044.
-
(1995)
C. R. Acad. Sci. III. Sci. Vie
, vol.318
, pp. 1037-1044
-
-
Aamiri, A.1
-
147
-
-
20444420498
-
Nondegradative sulfation of polysaccharides. Synthesis and structure characterization of biologically active heparan sulfate mimetics
-
Papy-Garcia D., et al. Nondegradative sulfation of polysaccharides. Synthesis and structure characterization of biologically active heparan sulfate mimetics. Macromolecules 2005, 38:4647-4654.
-
(2005)
Macromolecules
, vol.38
, pp. 4647-4654
-
-
Papy-Garcia, D.1
-
148
-
-
77952544052
-
Glycosaminoglycan mimetics trigger IP3-dependent intracellular calcium release in myoblasts
-
Martelly I., et al. Glycosaminoglycan mimetics trigger IP3-dependent intracellular calcium release in myoblasts. Matrix Biol. 2010, 29:317-329.
-
(2010)
Matrix Biol.
, vol.29
, pp. 317-329
-
-
Martelly, I.1
-
149
-
-
58149163003
-
Significant reduction in neural adhesions after administration of the regenerating agent OTR4120, a synthetic glycosaminoglycan mimetic, after peripheral nerve injury in rats
-
Zuijdendorp H.M., et al. Significant reduction in neural adhesions after administration of the regenerating agent OTR4120, a synthetic glycosaminoglycan mimetic, after peripheral nerve injury in rats. J. Neurosurg. 2008, 109:967-973.
-
(2008)
J. Neurosurg.
, vol.109
, pp. 967-973
-
-
Zuijdendorp, H.M.1
-
150
-
-
33845485024
-
RGTA OTR4120, a heparan sulfate mimetic, is a possible long-term active agent to heal burned skin
-
Garcia-Filipe S., et al. RGTA OTR4120, a heparan sulfate mimetic, is a possible long-term active agent to heal burned skin. J. Biomed. Mater. Res. A 2007, 80:75-84.
-
(2007)
J. Biomed. Mater. Res. A
, vol.80
, pp. 75-84
-
-
Garcia-Filipe, S.1
-
151
-
-
70350638975
-
Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120
-
Tong M., et al. Stimulated neovascularization, inflammation resolution and collagen maturation in healing rat cutaneous wounds by a heparan sulfate glycosaminoglycan mimetic, OTR4120. Wound Repair Regen. 2009, 17:840-852.
-
(2009)
Wound Repair Regen.
, vol.17
, pp. 840-852
-
-
Tong, M.1
-
152
-
-
0037114256
-
11, a heparan sulfate mimetic polymer, efficient on muscle regeneration
-
11, a heparan sulfate mimetic polymer, efficient on muscle regeneration. J. Biomed. Mater. Res. 2002, 62:525-531.
-
(2002)
J. Biomed. Mater. Res.
, vol.62
, pp. 525-531
-
-
Meddahi, A.1
-
153
-
-
45249101320
-
Pilot study of a new matrix therapy agent (RGTA OTR4120®) in treatment-resistant corneal ulcers and corneal dystrophy
-
Chebbi C.K., et al. Pilot study of a new matrix therapy agent (RGTA OTR4120®) in treatment-resistant corneal ulcers and corneal dystrophy. J. Fr. Opthalmol. 2008, 31:465-471.
-
(2008)
J. Fr. Opthalmol.
, vol.31
, pp. 465-471
-
-
Chebbi, C.K.1
-
155
-
-
78649636504
-
Neutralization of hemorrhagic and antithrombotic activities of heparins by a novel salicylamide derivative
-
(Meeting Abstracts 1)
-
Kuziej J., et al. Neutralization of hemorrhagic and antithrombotic activities of heparins by a novel salicylamide derivative. FASEB J. 2009, 23:566-569. (Meeting Abstracts 1).
-
(2009)
FASEB J.
, vol.23
, pp. 566-569
-
-
Kuziej, J.1
-
156
-
-
78649632442
-
Neutralization of the anticoagulant and anti-Xa effects of fondaparinux and idraparinux by a novel synthetic antagonist. Pharmacologic implications
-
(Meeting Abstracts 1)
-
Fareed J., et al. Neutralization of the anticoagulant and anti-Xa effects of fondaparinux and idraparinux by a novel synthetic antagonist. Pharmacologic implications. FASEB J. 2008, 22:1117-1118. (Meeting Abstracts 1).
-
(2008)
FASEB J.
, vol.22
, pp. 1117-1118
-
-
Fareed, J.1
-
158
-
-
13344294985
-
The synthesis of well-defined heparin and heparan sulfate fragments
-
Codée J.D.C., et al. The synthesis of well-defined heparin and heparan sulfate fragments. Drug Discov Today: Technol. 2004, 1:317-326.
-
(2004)
Drug Discov Today: Technol.
, vol.1
, pp. 317-326
-
-
Codée, J.D.C.1
-
159
-
-
84896702944
-
Small molecule inhibitors of glycosaminoglycan biosynthesisas substrate optimization therapy for the mucopolysaccharidoses
-
Brown J., et al. Small molecule inhibitors of glycosaminoglycan biosynthesisas substrate optimization therapy for the mucopolysaccharidoses. Mol. Genet. Metab. 2010, 99:S12-S112.
-
(2010)
Mol. Genet. Metab.
, vol.99
-
-
Brown, J.1
|